Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 5/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 7/20 | 0.53 |
| ▸ | LCK | P06239 | 3/20 | 0.53 |
| ▸ | SRC | P12931 | 2/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080682 | 0.86 | PDPK1 (0.55) | PDPK1PDGFRBRETLCKSRC | |
| SCHEMBL4084830 | 0.83 | NTRK1 (0.61) | PDPK1PDGFRBRETLCKSRC | |
| SCHEMBL15636480 | 0.82 | NTRK1 (0.58) | NTRK1 | |
| SCHEMBL4086560 | 0.79 | NTRK1 (0.64) | PDPK1PDGFRBRETLCKSRC | |
| SCHEMBL1942062 | 0.79 | PDGFRB (0.67) | PDPK1PDGFRBRETLCKSRC | |
| SCHEMBL4079290 | 0.79 | PDPK1 (0.64) | PDPK1PDGFRBRETLCKSRC | |
| SCHEMBL4078414 | 0.78 | NTRK1 (0.67) | PDPK1PDGFRBRETLCKSRC | |
| SCHEMBL1942060 | 0.78 | PDGFRB (0.66) | PDPK1PDGFRBRETLCKSRC | |
| SCHEMBL4086042 | 0.78 | NTRK1 (0.52) | PDPK1PDGFRBRETLCKSRC | |
| SCHEMBL4088496 | 0.77 | PDGFRB (0.63) | PDPK1PDGFRBRETLCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595325-B2 | Substituted pyrrolo[2,3-d]pyrimidine derivatives useful in cancer treatment | PFIZER INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1773836-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | Pfizer Products Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | PFIZER INC | 2006-02-16 | — | — | US | disclosed |
| WO-2005116035-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | TP53, DPYD, CCNT1 | PDPK1 947/4885PDGFRB 2700/4885RET 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.